Vor Biopharma Inc. Net Income
Vor Biopharma Inc. (VOR) reported Net Income of -$62.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Vor Biopharma Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$62.81M.
- Vor Biopharma Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$219.58M.
- Vor Biopharma Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.72B.
- Vor Biopharma Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$812.68M.
- Vor Biopharma Inc. net income (loss) attributable to parent for fiscal 2025 was -$695.98M.
- Vor Biopharma Inc. net income (loss) attributable to parent for fiscal 2024 was -$116.91M.
- Vor Biopharma Inc. net income (loss) attributable to parent for fiscal 2023 was -$117.86M.
- Vor Biopharma Inc. net income (loss) attributable to parent for fiscal 2022 was -$92.09M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$62.81M 10-Q · filed 2026-08-11 | -$282.39M 10-Q · filed 2026-08-11 | $1.44B derived: sum of 3 quarters · filed 2026-08-11 | $627.78M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$219.58M 10-Q · filed 2026-08-11 | -$219.59M 10-Q · filed 2026-05-13 | $1.50B derived: sum of 2 quarters · filed 2026-08-11 | $690.59M derived: sum of 3 quarters · filed 2026-08-11 | -$883.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.72B derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $910.17M derived: sum of 2 quarters · filed 2026-03-30 | -$663.50M derived: sum of 3 quarters · filed 2026-08-11 | -$695.98M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$812.68M 10-Q · filed 2025-11-13 | -$2.39B derived: sum of 2 quarters · filed 2026-08-11 | -$2.42B 10-Q · filed 2025-11-13 | -$2.45B derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$1.57B 10-Q · filed 2026-08-11 | -$1.61B 10-Q · filed 2026-08-11 | -$1.64B derived: sum of 3 quarters · filed 2026-08-11 | -$1.66B derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$32.49M 10-Q · filed 2026-08-11 | -$63.20M derived: sum of 2 quarters · filed 2026-08-11 | -$90.76M derived: sum of 3 quarters · filed 2026-08-11 | -$118.60M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2024-12-31 | -$30.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$58.27M derived: sum of 2 quarters · filed 2026-03-30 | -$86.11M derived: sum of 3 quarters · filed 2026-03-30 | -$116.91M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$27.56M 10-Q · filed 2025-11-13 | -$55.40M derived: sum of 2 quarters · filed 2025-11-13 | -$86.20M 10-Q · filed 2025-11-13 | -$112.46M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$27.84M 10-Q · filed 2025-11-13 | -$58.64M 10-Q · filed 2025-08-12 | -$84.90M derived: sum of 3 quarters · filed 2025-11-13 | -$118.09M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-03-31 | -$30.80M 10-Q · filed 2025-11-13 | -$57.06M derived: sum of 2 quarters · filed 2025-11-13 | -$90.25M derived: sum of 3 quarters · filed 2025-11-13 | -$120.23M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2023-12-31 | -$26.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$59.45M derived: sum of 2 quarters · filed 2025-03-20 | -$89.43M derived: sum of 3 quarters · filed 2025-03-20 | -$117.86M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$33.19M 10-Q · filed 2024-11-07 | -$63.17M derived: sum of 2 quarters · filed 2024-11-07 | -$91.60M 10-Q · filed 2024-11-07 | -$115.51M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$29.98M 10-Q · filed 2024-11-07 | -$58.41M 10-Q · filed 2024-08-08 | -$82.32M derived: sum of 3 quarters · filed 2024-11-07 | -$106.11M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | -$28.43M 10-Q · filed 2024-11-07 | -$52.34M derived: sum of 2 quarters · filed 2024-11-07 | -$76.13M derived: sum of 3 quarters · filed 2024-11-07 | -$97.79M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2022-12-31 | -$23.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$47.70M derived: sum of 2 quarters · filed 2024-03-20 | -$69.36M derived: sum of 3 quarters · filed 2024-03-20 | -$92.09M 10-K · filed 2024-03-20 | |
| 2022-09-30 | -$23.79M 10-Q · filed 2023-11-07 | -$45.45M derived: sum of 2 quarters · filed 2023-11-07 | -$68.18M 10-Q · filed 2023-11-07 | -$86.44M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$21.66M 10-Q · filed 2023-11-07 | -$44.40M 10-Q · filed 2023-08-10 | -$62.65M derived: sum of 3 quarters · filed 2023-11-07 | -$81.20M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-03-31 | -$22.74M 10-Q · filed 2023-11-07 | -$40.99M derived: sum of 2 quarters · filed 2023-11-07 | -$59.54M derived: sum of 3 quarters · filed 2023-11-07 | -$77.91M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2021-12-31 | -$18.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$36.81M derived: sum of 2 quarters · filed 2023-03-23 | -$55.18M derived: sum of 3 quarters · filed 2023-03-23 | -$68.90M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$18.55M 10-Q · filed 2022-11-10 | -$36.92M derived: sum of 2 quarters · filed 2022-11-10 | -$50.65M 10-Q · filed 2022-11-10 | -$66.31M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$18.37M 10-Q · filed 2022-11-10 | -$32.09M 10-Q · filed 2022-08-11 | -$47.76M derived: sum of 3 quarters · filed 2022-11-10 | -$59.54M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-03-31 | -$13.72M 10-Q · filed 2022-11-10 | -$29.39M derived: sum of 2 quarters · filed 2022-11-10 | -$41.17M derived: sum of 3 quarters · filed 2022-11-10 | -$49.21M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2020-12-31 | -$15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$27.45M derived: sum of 2 quarters · filed 2022-03-14 | -$35.49M derived: sum of 3 quarters · filed 2022-03-14 | -$43.34M 10-K · filed 2022-03-14 | |
| 2020-09-30 | -$11.79M 10-Q · filed 2021-11-10 | -$19.82M derived: sum of 2 quarters · filed 2021-11-10 | -$27.67M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$8.04M 10-Q · filed 2021-11-10 | -$15.89M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$7.85M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |